Use of poly-4hydroxybutyrate (P4HB) mesh in chronic mesh infection

Dr Jose Bueno will share insights on his latest study: Biosynthetic Resorbable Prosthesis is Useful in Single-Stage Management of Chronic Mesh Infection After Abdominal Wall Hernia Repair

Chronic mesh infection (CMI) is one of the most devastating complications after abdominal wall hernia repair (AWHR). Prosthesis explantation has been recommended when an infection is not resolved through conservative measures. However, the placement of new mesh during explantation has not been universally accepted. There is a high possibility of prosthesis reinfection even with biological scaffolds or permanent synthetic meshes. Consequently, two-stage management has been recommended as the ideal approach. This often results in the need for surgical procedures, such as autologous flap. reconstruction or additional mesh implantation, after the infection has been resolved.

The introduction of biosynthetic resorbable prostheses has led to new approaches and indications in cases of complex hernia repairs in contaminated fields. The use of these types of mesh for AWHR has shown a potential decrease in the hospital budget. The advantages, such as reabsorption after 15–18 months and the acceptable results in patients with risk factors and surgeries classified as Class II/III by the Centers for Disease Control (CDC), have led to wider indications for AWHR in contaminated fields. However, for CMI (CDC Class IV), biosynthetic resorbable prostheses have not previously been used in a one-stage treatment approach that involves the simultaneous removal of the infected mesh and placement of the absorbable scaffold.

About BD

BD is one of the largest global medical technology companies in the world and is advancing the world of health by improving medical discovery, diagnostics and the delivery of care. The company develops innovative technology, services and solutions that help advance both clinical therapy for patients and clinical process for health care providers. BD and its 65,000 employees have a passion and commitment to help improve patient outcomes, improve the safety and efficiency of clinicians’ care delivery process, enable laboratory scientists to better diagnose disease and advance researchers’ capabilities to develop the next generation of diagnostics and therapeutics. BD has a presence in virtually every country and partners with organizations around the world to address some of the most challenging global health issues. BD helps customers enhance outcomes, lower costs, increase efficiencies, improve safety and expand access to health care.

Find out more https://www.bd.com/en-uk

Contact us:

Alexander Erdmann, Marketing Manager Europe
Surgery - BD Interventional
alexander.erdmann@bd.com